Figure 4
From: Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Ezetimibe improved reactive hyperemia index (RHI) by EndoPAT™ in patients with hypercholesterolemia. RHI were measured before and after 22-week ezetimibe administration in patients with hypercholesterolemia (n = 14). According to Bonetti P.O., et al, [14], an RHI < 1.35 was found to have a sensitivity of 80% and a specificity of 85% to identify patients with coronary endothelial dysfunction. Bars represent the mean value of the ratio ± SD.